RASL10A is a small GTPase belonging to the RAS superfamily that functions as a potent inhibitor of cellular proliferation 1. As a GTPase, RASL10A participates in small GTPase-mediated signal transduction and exhibits sex-dependent differences in transcript expression across tissues 2. Mechanistically, RASL10A suppresses transforming growth factor-beta (TGF-β)-induced epithelial-mesenchymal transition (EMT) and subsequent cellular invasion by inhibiting Smad3 phosphorylation and Snail expression in lung adenocarcinoma cells 1. In clinical contexts, RASL10A expression inversely correlates with patient prognosis in lung adenocarcinoma, where low expression is associated with poor outcomes 1. Additionally, epigenetic alterations affecting RASL10A, specifically CpG methylation in its promoter region, have been identified as potentially predictive of opioid dosage response in patients receiving therapeutic opioids 3. These findings position RASL10A as a novel tumor suppressor candidate and potential therapeutic target for controlling metastatic progression in lung adenocarcinoma and other malignancies.